metastatic-breast-cancer
(3)
Zetagen Therapeutics
Zetagen Therapeutics is a private, clinical-stage biopharmaceutical company based in Syracuse, New York, developing locally-administered therapies for metastatic and primary cancers that spread to bone. Its lead candidate, ZetaMet (Zeta-BC-003), uses a patented molecular pathway delivered by a single outpatient injection to suspend cancer growth, inhibit pain, and regenerate bone in patients with metastatic breast cancer lytic lesions. Spun out of research at SUNY Upstate Medical University in 2015, the company has earned multiple FDA Breakthrough Designations and reported Phase 2a data showing an 87.9% mean reduction in lesion defect volume.
Manta Cares
Manta Cares is a San Francisco-based digital health company redesigning the cancer experience for patients and caregivers. Founded by breast cancer survivor Samira Daswani, it offers a free, HIPAA-compliant, AI-enabled platform - featuring subway-style Cancer Maps, a symptom and appointment planner, and expert-reviewed resources vetted by 100+ oncologists - that turns the chaotic cancer journey into a navigable path. The company launched publicly in November 2025 with an oversubscribed $5.4M seed round led by Pear VC and Sozo Ventures.
Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company based in San Francisco that develops targeted small-molecule therapies for ER+/HER2- metastatic breast cancer and other women's cancers. Its lead candidate, palazestrant (OP-1250), is an oral complete estrogen receptor antagonist and selective ER degrader now in two Phase 3 trials, while a second program, OP-3136, is a KAT6 inhibitor in Phase 1. Olema's bet is that better-designed oral endocrine therapy can overcome the resistance that limits today's standard of care.